louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05747365: Role of Endocrine Disruptors in Thyroid Cancer
Official title: Cross-sectional Case-control Study on the Role of Endocrine Disruptors in Thyroid Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Endocrine Disruptor Chemicals
Thyroid Cancer
Lead sponsor: Istituto Auxologico Italiano
Sponsor class: OTHER
First posted: 2023-02-28
Enrollment: 222
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all patients referred to our tertiary clinical center for thyroid cancer diagnosed in the last 5 years will be consecutively enrolled (case population). Patients without a diagnosis of thyroid cancer will match patients included in the case population, according to age and sex.

Brief summary: the relationship between human exposure to EDCS and TC is poorly investigated and still unclear. The aim of this study is to evaluate the possible role of old and new generation endocrine disruptors in thyroid cancer. The primary aim is to evaluate the difference in the average levels of the main endocrine disruptors (PFAS, including: PFOA, PFOS, PFDA, PFUnA, PFHpS and possibly subsequently other categories, such as bisphenols, phthalates, parabens, PCBs, flame retardants) between patients with and without a diagnosis of thyroid cancer through highly sensitive, selective and precise mass spectrometry methods, such as liquid chromatography combined with tandem mass spectrometry (LC-MS / MS).

The secondary aim is to evaluate the relationship between the concentrations of endocrine disruptors and some anamnestic variables studied (for example the type of diet, the use of personal care products).


Eligibility criteria: Inclusion Criteria:

* patients with a diagnosis of thyroid cancer in the last 5 years (arm A)
* patients without a diagnosis of thyroid cancer will match patients included in arm A

Exclusion Criteria:

* subjects under 18 years old
* patients unable to sign the informed consent or questionnaires

Primary outcomes:
measure: Difference in the average levels of the main endocrine disruptors
timeFrame: At recruitment
measure: Relationship between the concentrations of endocrine disruptors and anamnestic variables
timeFrame: At recruitment
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Istituto Auxologico Italiano, IRCCS
Study officials:
References:
Clinical trial NCT05985265: Nano Fat Injection With or Without Fractional Carbon Dioxide Laser in Acne Scars
Official title: Assessment of Nano Fat Grafting Combined With Fractional Carbon Dioxide Laser Resurfacing Versus Nano Fat Grafting Alone in Atrophic Facial Acne Scars
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Acne Scars - Atrophic
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 50
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Assessment of nano fat grafting combined with carbon dioxide laser resurfacing versus nano fat grafting alone in treating facial atrophic acne scars

Detailed description: Acne scars is a world wide problem .though lots of treatment exists still mo gold standard for treatment of acne scars in this study.

Assessment of nano fat grafting combined with carbon dioxide laser resurfacing versus nano fat grafting alone in treating facial atrophic acne scars

Eligibility criteria: Inclusion Criteria:

* patients older than 18 years who attend the Outpatient Clinics of Dermatology and Plastic Surgery Departments, Assiut University Hospital, with moderate to severe atrophic facial acne scars on both cheeks, as assessed using the Goodman and Baron Qualitative scar grading system (12), will be enrolled in the study.

Exclusion Criteria:

* include: pregnancy or lactation; active acne, history of deep chemical peeling or filler injection in the previous 6 months, history of keloid or hypertrophic scar formation; use of isotretinoin in the previous 6 months; active infection in the treatment area; bleeding tendencies; history of herpes simplex or herpes zoster infection on the face; and patients with unrealistic expectations.

Primary outcomes:
measure: Clinical assessment of acne scar severity
timeFrame: up to 24 weeks
Secondary outcomes:
measure: Physician global assessment
timeFrame: up to 24 weeks
measure: percent of reduction in scar count
timeFrame: up to 24 weeks
measure: Patient satisfaction
timeFrame: 1 year
measure: Adverse events
timeFrame: 1 year
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Faculty of Medicine, Assiut University
Study officials:
affiliation: Department of Plastic Surgery, professor
name: youssef S farrag, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Plastic Surgery , Assistant lecture
name: Wael S Ibraheem, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Goodman GJ, Baron JA. Postacne scarring: a qualitative global scarring grading system. Dermatol Surg. 2006 Dec;32(12):1458-66. doi: 10.1111/j.1524-4725.2006.32354.x.
citation: Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. J Am Acad Dermatol. 2001 Jul;45(1):109-17. doi: 10.1067/mjd.2001.113451.
citation: Chan NP, Ho SG, Yeung CK, Shek SY, Chan HH. Fractional ablative carbon dioxide laser resurfacing for skin rejuvenation and acne scars in Asians. Lasers Surg Med. 2010 Nov;42(9):615-23. doi: 10.1002/lsm.20974.
Clinical trial NCT03749265: Rate Of Residual Clubfoot Deformity With Correlation To Absence Of Peroneus Tertius Muscle
Official title: Rate Of Residual Clubfoot Deformity With Correlation To Absence Of Peroneus Tertius Muscle: A Prospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Clubfoot
Keywords: Peroneus Tertius Muscle
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2018-11-21
Enrollment: 75
Sex: ALL
Minimum age (years): 5
Maximum age (years): 120
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients aged 5-17 years , which were treated with the Ponseti technique for Clubfoot in HaEmek medical center, and have sufficient data/follow-up about them in medical records

Brief summary: Rate Of Residual Clubfoot Deformity With Correlation To Absence Of Peroneus Tertius Muscle , A Prospective Study.


Eligibility criteria: Inclusion Criteria:

* patients aged 5-17 years , which were treated with the Ponseti technique for Clubfoot in HaEmek medical center, and have sufficient data/follow-up about them in medical records /

Exclusion Criteria:

* patients aged\< 5 years
* Neurological Clubfoot
* patients with insufficient data in medical records
* clubfoot caused by arthrogryposis , connective tissue diseases and congenital fibular hemimelia

Primary outcomes:
measure: Presence or Absence of peroneus tertius
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: haemek medical center
name: Eytan Dujovni, senior
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05322265: Complication in Laparoscopic Renal and Adrenal Surgery (CLARAS)
Official title: Complication in Laparoscopic Renal and Adrenal Surgery (CLARAS): an International Multicenter Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Adrenal Disease
Renal Cancer
Surgery--Complications
Keywords: laparoscopic surgery
renal surgery
adrenalectomy
complication in laparoscopic surgery
Lead sponsor: University of Palermo
Sponsor class: OTHER
Collaborators: name: Fundacio Puigvert
First posted: 2022-04-11
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all patients underwent to laparoscopic renal and adrenal surgery form april 2017 to march 2022 in several high volume surgical center

Brief summary: the aim of this study is clarify complication and their resolution in laparoscopic renal and adrenal surgery.

Detailed description: the aim of this study is clarify complication and their resolution in laparoscopic renal and adrenal surgery.

Eligibility criteria: Inclusion Criteria:

renal diseases with indication to surgery adrenal masses

Exclusion Criteria:

open surgery in principle

Primary outcomes:
measure: intraoperative complications
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Palermo
country: Italy
facility: University of Palermo
Study officials:
affiliation: University of Palermo
name: Antonino Agrusa, Medicine
role: STUDY_DIRECTOR
References:
Clinical trial NCT03448965: Hypoglycemic and Hyperglycemic Disorders
Official title: Glycemic Disorders in Low Birth Weight Babies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypoglycemia in Newborn Infants
Hyperglycemia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-02-28
Enrollment: 100
Sex: ALL
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all low birth weight babies

Brief summary: Definition of low birth weight:

Low birth weight infants are those born weighing less than 2500 g. These are further subdivided into:

* Very Low Birth Weight : Birth weight \<1,500 g
* Extremely Low Birth Weight : Birth weight \<1,000 g Their survival is directly related to birth weight, with approximately 20% of those between 500 and 600 g and\>90% of those between 1,250 and 1,500 g surviving. Perinatalcare has improved the rate of survival of low birth weight infants.

Detailed description: Causes of low birth weight:

* Premature birth
* Intrauterine growth restriction, which are most often Due to different placental problems and health problems of the mother or new-born

RISK FACTORS:

* Age: Teen mothers have a much higher risk of having VLBW infant.
* Multiple birth babies are at increased risk of being VLBW because they often are premature. More than 50% of twins and other multiple gestations are VLBW if \<15 years
* Maternal health: Women exposed to drugs, alcohol, and cigarettes during pregnancy are more likely to have low birth weight babies. Mothers of lower socioeconomic
* Race: African-American babies are twice as likely as Caucasian to be very low birth weight

Eligibility criteria: Inclusion Criteria:

* All neonates admitted to neonatology unit

  1. From 0-28 days
  2. Weighting less than 2500gm

Exclusion Criteria:

* Any neonate weighting more than 2500 gm

Primary outcomes:
measure: glycemic disorders in low birth weight
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Abdulkadir I, Hassan L, Abdullahi F, Sobowale AM, Akeredolu FD, Purdue S, Okpe M, Adewumi OA, Abdullahi U, Onadiran MA, Ogala WN. Outcome of Extremely Low Birth Weight Babies in Zaria; A Ten-Year Review. West Afr J Med. 2015 Jan-Mar;34(1):50-4.
citation: Hays SP, Smith EO, Sunehag AL. Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants. Pediatrics. 2006 Nov;118(5):1811-8. doi: 10.1542/peds.2006-0628.
citation: Rozance PJ, Hay WW Jr. New approaches to management of neonatal hypoglycemia. Matern Health Neonatol Perinatol. 2016 May 10;2:3. doi: 10.1186/s40748-016-0031-z. eCollection 2016.
citation: Eichenwald EC, Stark AR. Management and outcomes of very low birth weight. N Engl J Med. 2008 Apr 17;358(16):1700-11. doi: 10.1056/NEJMra0707601. No abstract available.
Clinical trial NCT05553457: MyHand-SCI: an Active Hand Orthosis for Spinal Cord Injury
Official title: MyHand-SCI: a Wearable Robotic Hand Orthosis for C6-C7 Spinal Cord Injury
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Spinal Cord Injuries
Tetraplegia
Keywords: Spinal Cord Injuries
Tetraplegia
Rehabilitation
Robotics
Assistive Technology
Wearable Devices
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2022-09-23
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to develop and test the hardware and software components of the MyHand-SCI device to assist with hand function for individuals with C6-C7 spinal cord injury.

Detailed description: The purpose of this study is to develop and test the hardware and software components of the MyHand-SCI device to assist with hand function for individuals with C6-C7 spinal cord injury. This is a non-randomized exploratory study to determine feasibility of device use, provide user feedback on device features and function to allow further refinement of the device, and assess the utility and responsiveness of several clinical outcome measures.

Eligibility criteria: Inclusion Criteria:

* Individuals with C6-C7 spinal cord injury, at least 6-months post-injury with impaired upper limb function
* Substantially reduced motor control and strength below the level of their SCI with regard to hand and finger function
* Able to provide informed consent

Exclusion Criteria:

* Fixed upper limb contractures that limit functional use of the hand and arm or ability to use the device
* Severe spasticity (modified Ashworth \>2) at elbow, wrist, or fingers
* Any open wounds or unusual skin fragility
* Persistent severe pain in their upper limb

Primary outcomes:
measure: System Usability Scale
timeFrame: Up to 2 years at study completion
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Irving Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Joel Stein, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01198457: Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
Official title: BONA (Adherence of Patients to Bonefos Therapy). Prospective Observational Non-interventional Study of Adherence of Patients to Bonefos Medication in Relation to Analgesic Effect and Incidence of Skeletal Events
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Neoplasms
Prostatic Neoplasms
Multiple Myeloma
Osteolysis
Keywords: Clodronate
Compliance
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2010-09-10
Enrollment: 147
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Random group of patients in oncology clinic

Brief summary: Adherence (or compliance with) a medication regimen is generally defined as the extent to which patients take medication as prescribed by their health care providers. The adherence to medications has close relation to effectiveness of the therapy. The primary objective of this study is to observe the adherence to treatment with oral clodronate (PDC, proportion of days covered, number of days in which clodronate is taken according to treating physician recommendation) in patients with malignancy. The secondary "hypothesis generating" objective is to describe the relation between adherence to treatment with oral clodronate and efficacy of the therapy (skeletal events, pain).


Eligibility criteria: Inclusion Criteria:

* Diagnosis of breast cancer, prostate cancer, multiple myeloma and other skeletal events causing tumors
* Bone metastases
* Therapy with clodronate (1600 mg per day, 800 mg tablets) according to SmPC (Summary of Product Characteristics) Bonefos.
* By agreeing to usage of patients diaries and goodwill with accounting of tablets

Exclusion Criteria:

* According to SmPC (Summary of Product Characteristics) Bonefos.

Primary outcomes:
measure: Adherence to treatment with oral clodronate (PDC, proportion of days covered).
timeFrame: 12 months of therapy.
Secondary outcomes:
measure: Efficacy evaluation of the therapy based on incidence of skeletal events
timeFrame: 12 months
measure: Efficacy of the therapy in pain releif will be investigated exploratory based on questionnaire
timeFrame: 12 months
Other outcomes:
Locations:
city: Many Locations
country: Czech Republic
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT06046157: Oral Motor Intervention for Preterm Babies
Official title: Effect of Oral Motor Intervention on Feeding Parameters in Preterm Babies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Preterm Babies
Keywords: Premature infant oral motor intervention (PIOMI)
Premature
Nutrition
Lead sponsor: Ataturk University
Sponsor class: OTHER
Collaborators: name: MSc İlknur Budancamanak
name: Professor Kadir Şerafettin Tekgündüz
name: Associate Professor Mustafa Kara
name: MSc Ebru Betül Albayrak
First posted: 2023-09-21
Enrollment: 24
Sex: ALL
Minimum age (years): 28
Maximum age (years): 32
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to evaluate the effect of oral motor intervention (PIOMI) applied to preterm babies along with the smell and taste of breast milk on feeding parameters and the transition time to oral feeding. The main questions it aims to answer are:

* Does affect nutritional parameters PIOMI with the smell of breast milk?
* Does affect nutritional parameters PIOMI with breast milk taste? Participants will consist of breast milk-scented PIOMI, breast milk-tasting PIOMI and control groups.

Researchers will compare breast milk-scented PIOMI, breast milk-tasting PIOMI and control groups to see if early feeding skills.

Detailed description: The preterm newborn population is potentially unable to be fed orally for a long time during the postnatal period. Since the physiological functions of preterm babies have not yet matured, their adaptation to the external uterine environment is more complicated. This also means long hospital stays for premature babies. One of the main criteria for a preterm baby to be discharged from the hospital is to be able to feed orally.

Premature oral motor intervention (PIOMI) is included in the literature as one of the treatment programs to improve the oral motor control and neurobehavioral status of preterm babies. No study design has been found regarding PIOMI, which is applied to preterm babies with the smell and taste of breast milk. This research was planned to evaluate the effect of oral motor intervention (PIOMI) applied to preterm babies along with the smell and taste of breast milk on feeding parameters.

Eligibility criteria: Inclusion Criteria:

* Breastfed,
* Preterm babies with a gestational age of 28-32 weeks,
* No facial deformity,
* No respiratory, cardiovascular, gastrointestinal or neurological disorders or syndromes that would prevent or complicate oral feeding,
* It will produce preterm babies who are not fed orally but are fed via tube (orogastric).

Exclusion Criteria:

* Having respiratory distress,
* Babies who do not receive informed consent form from the parents will not be included.

Primary outcomes:
measure: Early feeding skills
timeFrame: 12 week
Secondary outcomes:
Other outcomes:
Locations:
city: Erzurum
country: Turkey
facility: Ataturk University
Study officials:
References:
Clinical trial NCT01982357: Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies
Official title: Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infant, Premature, Diseases
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
Collaborators: name: Beckman Laser Institute University of California Irvine
First posted: 2013-11-13
Enrollment: 32
Sex: ALL
Minimum age (years): 1
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Study population will be selected from University of California Irvine Medical Center at Neonate Intensive Care Unit

Brief summary: Alterations to microvascular blood flow in premature infants, are known to contribute to several major disease entities.

The optically-measured tissue blood flow, to determine tissue perfusion that can be use to detect blood loss.

Detailed description: The researchers want to use optical technologies to non-invasively detect blood flow that can tell the onset of blood loss. The research can measure blood flow in stable premature infants in the Neonatal Intensive Care Unit over the duration of several weeks.

The technologies are Laser Speckle Imaging and Diffuse Optical Spectroscopy.

Laser Speckle Imaging non-contact imaging technology, is sensitive to blood flow in superficial tissues. Diffuse Optical Spectroscopy, a probe-based contact technology like pulse oximetry, measures hemoglobin concentrations and states deeper below the skin surface.

Eligibility criteria: Inclusion Criteria:

* premature infants born or transferred to neonatal intensive care unit with a gestational age of 28-35 weeks

Exclusion Criteria:

* NONE premature infants born or transferred to neonatal intensive care unit

Primary outcomes:
measure: Normal Blood flow in premature infant
timeFrame: up to 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Orange
country: United States
facility: UCIMC
state: California
Study officials:
affiliation: Beckman Laser Institute, UCI
name: Omid Fathi, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Beckman Laser Institute, UCI
name: Bernard Choi, PhD
role: STUDY_DIRECTOR
References: